With a simple urine test it allows to improve the selection of patients who would benefit from a biopsy, and helps evade it in cases where it is unnecessary.
Based on the mRNA identification of the DLX1 and HOXC6 genes, it is possible to distinguish which patients are at increased risk of clinically significant cancer from those who do not.
Providing a negative predictive value of 99.6% for Gleason Score equal to or greater than 8 and 98% for GS equal to or greater than 7, this means that when this test determines that the risk for an aggressive cancer is low it has a very small margin Of error.
1- MEN WITH HIGH RISK can benefit from biopsy and early detection.
2- MEN WITH VERY LOW RISK can avoid having to undergo unnecessary invasive procedures with routine follow-ups and screenings.